Keyphrases
Pentostatin
100%
PENTO
100%
Allogeneic
100%
Alemtuzumab
100%
Transplantation
100%
Specific Intent
40%
Donor Cells
40%
Peripheral Blood Progenitor Cells
40%
Lymphocyte Cytotoxicity
20%
Laboratory Research
20%
Rational Development
20%
Anti-CD52 Monoclonal Antibody
20%
Graft-versus-host Disease (GvHD)
20%
Pharmacodynamic Interactions
20%
T-cell Receptor Excision Circles
20%
Cellular Reconstitution
20%
Continuous Infusion
20%
Nonmyeloablative
20%
Circle Analysis
20%
Deoxycoformycin
20%
Treatment Toxicity
20%
Purine nucleoside Analogues
20%
Immunosuppression
20%
Matched Related
20%
Cell Engraftment
20%
Non-relapse Mortality
20%
Donor chimerism
20%
Safety Endpoints
20%
Reversible Inhibition
20%
Matched Unrelated
20%
Clinical Research
20%
Renal Cell Carcinoma
20%
T Cells
20%
Event-free Survival
20%
Cytopenia
20%
Myeloid Cells
20%
Myelosuppression
20%
Hematologic
20%
Myeloablative
20%
High-risk Subjects
20%
Mortality Risk
20%
Hematological Malignancies
20%
Reconstitution
20%
Humanized
20%
Myelosuppressive
20%
Apoptosis
20%
Engraftment
20%
Lysis
20%
Immunosuppressive Regimens
20%
IgG1
20%
Reduced Intensity
20%
Bone Marrow
20%
Phase II Trial
20%
Neutropenia
20%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
20%
Campath
20%
Myelotoxicity
20%
Antibody-dependent Cellular Cytotoxicity
20%
Reduced Dose
20%
Thymic Output
20%
Apoptosis Induction
20%
Cell-to-cell
20%
Preparative Regimen
20%
Cell Transplantation
20%
Adenosine Deaminase
20%
HLA Matching
20%
High Risk
20%
Total Dose
20%
Immunological Effects
20%
Efficacy Endpoint
20%
Medicine and Dentistry
Pentostatin
100%
Alemtuzumab
100%
Immunosuppressive Drug
50%
Cell Transplantation
50%
Progenitor Cell
50%
Programmed Cell Death
50%
Engraftment
50%
Bone Marrow Suppression
25%
Clear Cell Renal Cell Carcinoma
25%
Myeloid Cell
25%
Purine Nucleoside Derivative
25%
Bone Marrow Toxicity
25%
Continuous Infusion
25%
Event Free Survival
25%
Injury
25%
Immunoglobulin G1
25%
Immunosuppressive Treatment
25%
T Cell
25%
Cytopenia
25%
T Lymphocyte Receptor
25%
Lymphocytotoxicity
25%
Adenosine Deaminase
25%
Pharmacodynamics
25%
Antibody Dependent Cellular Cytotoxicity
25%
Graft Versus Host Reaction
25%
Chimera
25%
Neutropenia
25%
Hematologic Malignancy
25%
Hematopoietic Stem Cell
25%
Phase II Trials
25%
Immunology and Microbiology
Alemtuzumab
100%
Immunosuppressive Drug
50%
Engraftment
50%
Cell Transplantation
50%
Graft-Versus-Host Disease
25%
T Cell
25%
Adenosine Deaminase
25%
Immunoglobulin G1
25%
Immunosuppression
25%
Pharmacodynamics
25%
Myeloid
25%
Carcinoma Cell
25%
Lymphocytotoxicity
25%
T-Cell Receptor Excision Circles
25%
Chimera
25%
Hematopoietic Cell
25%
Antibody-Dependent Cell-Mediated Cytotoxicity
25%
Event Free Survival
25%